Xeligekimab (development code GR1501; trade name Jinlixi) is a monoclonal antibody that neutralizes interleukin-17A; it is being developed for plaque psoriasis, axial spondyloarthritis, and lupus nephritis.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.